Skip to content Skip to footer
Subscribe Now
Verona Pharma
NEWS

Verona Pharma’s Ohtuvayre (Ensifentrine) Receives the US FDA’s Approval to Treat Chronic Obstructive Pulmonary Disease (COPD) 

Shots:  The US FDA has approved Ohtuvayre as a maintenance therapy to treat COPD patients, with its launch anticipated in Q3’24  The approval was based on the P-III (ENHANCE-1 & ENHANCE-2) studies analyzing Ohtuvayre monotx. or in addition with other maintenance therapies. Trials reached their 1EPs showing improved lung function; results were published in the…
June 26, 2024

Read more

Viewpoints_Konstantin Mehl
VIEWPOINTS

PharmaShots Interview: Kaia Health’s Konstantin Mehl Shares Insight on the Funding to Transform the Treatment for MSK and COPD

In an interview with PharmaShots, Konstantin Mehl, President, CEO, and Founder at Kaia Health shared his views on the grant of $75M Series C funding to expand clinical capabilities & transform the treatment path for musculoskeletal (MSK) and chronic obstructive pulmonary disease (COPD) care in the US and EU. Shots: The funding will extend the offering within EU and…
August 11, 2021

Read more

Viewpoints_Dr. Maria Ines Mitrani
VIEWPOINTS

PharmaShots Interview: Organicell’s Dr. Maria Ines Mitrani Shares Insights on the Zofin for COVID-19

In an interview with PharmaShots, Mari Mitrani, Chief Science Officer of Organicell shares her views on the positive results from the first ten COVID-19 patients treated with Zofin in India. Shots: This initial trial is being conducted in conjunction with Organicell's Indian partner, CWI India, which has entered into a product testing and distribution agreement with Organicell…
June 15, 2021

Read more

Viewpoint_Jonas_Duss_2021
VIEWPOINTS

PharmaShots Interview: Kaia Health’s Jonas Duss Shares Insights on COPD Pulmonary Rehabilitation App

In a recent interview with PharmaShots, Jonas Duss, US CEO and Co-Founder at Kaia Health shared his views on the Kaia Health's COPD Pulmonary Rehabilitation App and their collaboration with Chiesi Group to commercialize the app in EU. Shots: Kaia Health signs an exclusive agreement with Chiesi Group to commercialize the Kaia Health COPD Pulmonary Rehabilitation…
January 19, 2021

Read more

Viewpoint_Dr. Riju_Ray_2021
VIEWPOINTS

PharmaShots Interview: GSK’s Dr. Riju Ray Shares Insights on the Role of Community-Based Pulmonologists in Improving COPD Management Among PCPs

In a recent interview with PharmaShots, Dr. Riju Ray, MD, PhD, Senior Medical Lead at GSK, leading US medical affairs across asthma and COPD shared his views on how community-based pulmonologists are improving COPD management and education among referring PCPs. Shots: Pulmonologists identified 12 strong to moderate predictors of future COPD exacerbations, some of which were evaluated…
January 7, 2021

Read more